The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy can help people with excess weight and obesity lose ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

It might sound shocking to read about such drastic actions, but it’s stories of overweight children being bullied and too ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...